Skip to content
Head to head

Pacira BioSciences vs Takeda Pharmaceutical

Side-by-side on the measures that matter, with a plain-English read. Full detail: PCRX · TAK

Updated moments ago

1-year performance, rebased to 100

PCRX +52.8%TAK +53.0%
Takeda Pharmaceutical edges it on the scoreable measures. Takeda Pharmaceutical has the highest Quant Rating (88); Takeda Pharmaceutical has done best over the past year (+57%); Takeda Pharmaceutical pays the highest dividend yield.
PCRXTAK
Snapshot
Sector----
Last price36.4821.77
Change today+0.00%+1.68%
1-year return+49.6%+57.5%
Market cap$1.46B$69.76B
52-week range18.80 – 36.6713.92 – 22.07
Valuation
P/E (TTM)39.23311.00
P/E percentile, own 5-yr range44th100th
P/B2.051.50
Dividend yield0.00%1.44%
Profitability & growth
EPS (TTM)0.16-0.30
Net profit (TTM)$6.42M$-970.94M
Revenue (TTM)$743.30M$4.69T
Provider revenue period date2026-09-292026-09-29
Revenue growth (YoY)-1.6%+6.7%
Gross margin78.7%65.8%
Operating margin3.0%14.3%
Net margin5.1%0.9%
Free cash flow (TTM)$169.00M$433.95B
Provider cash-flow period date2026-09-292026-09-29
Ownership & sentiment
Institutional ownership113.6%51.3%
Insider activity (12mo)23 buy / 27 sell19 buy / 31 sell
Short interest (% of float)8.4%0.1%
Analyst consensus100% hold (9)100% buy (1)
Analyst price target$35 (-5%)$50 (+132%)
StockVane view
StockVane Quant RatingC (86)C (88)
Company
Employees82947,029
Founded20061781

▲ marks the more favourable stock(s) on measures with a clear direction (lower P/E, higher yield, higher Quant Rating, better 1-year return). Analyst consensus counts each covering institution once, at its most recent rating. Not a recommendation. Quant Rating method: Data & Methodology.